Shank-interacting protein–like 1 promotes tumorigenesis via PTEN inhibition in human tumor cells
Open accessThe DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Abstract
Inactivation of phosphatase and tensin homolog (PTEN) is a critical step during tumorigenesis, and PTEN inactivation by genetic and epigenetic means has been well studied. There is also evidence suggesting that PTEN negative regulators (PTEN-NRs) have a role in PTEN inactivation during tumorigenesis, but their identity has remained elusive. Here we have identified shank-interacting protein-like 1 (SIPL1) as a PTEN-NR in human tumor cell lines and human primary cervical cancer cells. Ectopic SIPL1 expression protected human U87 glioma cells from PTEN-mediated growth inhibition and promoted the formation of HeLa cell-derived xenograft tumors in immunocompromised mice. Conversely, siRNA-mediated knockdown of SIPL1 expression inhibited the growth of both HeLa cells and DU145 human prostate carcinoma cells in vitro and in vivo in a xenograft tumor model. These inhibitions were reversed by concomitant knockdown of PTEN, demonstrating that SIPL1 affects tumorigenesis via inhibition of PTEN function. Mechanistically, SIPL1 was found to interact with PTEN through its ubiquitin-like domain (UBL), inhibiting the phosphatidylinositol 3,4,5-trisphosphate (PIP3) phosphatase activity of PTEN. Furthermore, SIPL1 expression correlated with loss of PTEN function in PTEN-positive human primary cervical cancer tissue. Taken together, these observations indicate that SIPL1 is a PTEN-NR and that it facilitates tumorigenesis, at least in part, through its PTEN inhibitory function.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
PI3K pathway alterations in cancer: variations on a theme
Yuan, T. L., & Cantley, L. C. (2008) · Oncogene · doi:10.1038/onc.2008.245 · Cited by 1,845
The Multiple Roles of PTEN in Tumor Suppression
Di Cristofano, A., & Pandolfi, P. P. (2000) · Cell · doi:10.1016/s0092-8674(00)80674-1 · Cited by 1,182
CIP2A inhibits PP2A in human malignancies
Junttila, M. R., Puustinen, P., Niemelä, M., Ahola, R., Arnold, H., Böttzauw, T., Ala-aho, R., Nielsen, C., Ivaska, J., Taya, Y., et al. (2007) · Cell · doi:10.1016/j.cell.2007.04.044 · Cited by 677 · cited 1×
“To further examine the role of endogenous SIPL1 in inhibiting endogenous PTEN function during tumor formation, we employed a system used by others to knock down SIPL1 in order to determine its impact on xenograft tumor formation (34).”
MethodGoel, A., Arnold, C. N., Niedzwiecki, D., Carethers, J. M., Dowell, J. M., Wasserman, L., Compton, C., Mayer, R. J., Bertagnolli, M. M., & Boland, C. R. (2004) · Cancer Research · doi:10.1158/0008-5472.can-2401-2 · Cited by 302 · cited 1×
“Discussion While expression of the PTEN gene is frequently repressed by genetic alterations and by hypermethylation of the PTEN promoter in human cancers (4, 14, 15), inactivation of PTEN may also be mediated by putative PTEN-NRs.”
BackgroundLim, S., Sala, C., Yoon, J., Park, S., Kuroda, S., Sheng, M., & Kim, E. (2001) · Molecular and Cellular Neuroscience · doi:10.1006/mcne.2000.0940 · Cited by 151 · cited 4×
“Although SIPL1 has been shown to associate with SHANK in the postsynaptic density of synapses and may play a role in enteric neural transmission (32, 33), the function of SIPL1 remains largely to be determined.”
BackgroundResultInfluential
Cited by
The functions and regulation of the PTEN tumour suppressor
Song, M. S., Salmena, L., & Pandolfi, P. P. (2012) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3330 · Cited by 1,926
The functions and regulation of the PTEN tumour suppressor: new modes and prospects
Lee, Y.-R., Chen, M., & Pandolfi, P. P. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-018-0015-0 · Cited by 917
Worby, C. A., & Dixon, J. E. (2014) · Annual Review of Biochemistry · doi:10.1146/annurev-biochem-082411-113907 · Cited by 535
PTEN Tumor Suppressor Network in PI3K-Akt Pathway Control
Georgescu, M.-M. (2010) · Genes & Cancer · doi:10.1177/1947601911407325 · Cited by 482
PTEN function: the long and the short of it
Hopkins, B. D., Hodakoski, C., Barrows, D., Mense, S. M., & Parsons, R. E. (2014) · Trends in Biochemical Sciences · doi:10.1016/j.tibs.2014.02.006 · Cited by 309
SHARPIN is an endogenous inhibitor of β1-integrin activation
Rantala, J. K., Pouwels, J., Pellinen, T., Veltel, S., Laasola, P., Mattila, E., Potter, C. S., Duffy, T., Sundberg, J. P., Kallioniemi, O., et al. (2011) · Nature Cell Biology · doi:10.1038/ncb2340 · Cited by 201
“SHARPIN has been shown to bind to phosphatase and tensin homologue (PTEN) and inhibit its lipid phosphatase activit”
Li, J., Lai, Y., Cao, Y., Du, T., Zeng, L., Wang, G., Chen, X., Chen, J., Yu, Y., Zhang, S., et al. (2015) · Medical Oncology · doi:10.1007/s12032-014-0444-3 · Cited by 91
“[14] demonstrated that knockdown of SHARPIN reduced Akt activation in multiple cells but did not observe significant increases in Akt activation upon overexpression of SHARPIN in DU145 cells, suggesting that SHARPIN may require additional Fig.”
BackgroundElevation of SIPL1 (SHARPIN) increases breast cancer risk
De Melo, J., & Tang, D. (2015) · PLOS ONE · doi:10.1371/journal.pone.0127546 · Cited by 33
“The intensity values obtained from the Imagescope software after analyses were converted to an HScore using the formula [HScore = (% Positive) x (intensity) + 1] [20].”
BackgroundMethodSelf-citationMutually exclusive roles of SHARPIN in integrin inactivation and NF-κB signaling
De Franceschi, N., Peuhu, E., Parsons, M., Rissanen, S., Vattulainen, I., Salmi, M., Ivaska, J., & Pouwels, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0143423 · Cited by 22
A functional variant of SHARPIN confers increased risk of late-onset Alzheimer’s disease
Asanomi, Y., Shigemizu, D., Akiyama, S., Miyashita, A., Mitsumori, R., Hara, N., Ikeuchi, T., Niida, S., & Ozaki, K. (2022) · Journal of Human Genetics · doi:10.1038/s10038-021-00987-x · Cited by 19
The Sharpin interactome reveals a role for Sharpin in lamellipodium formation via the Arp2/3 complex
Khan, M. H., Salomaa, S. I., Jacquemet, G., Butt, U., Miihkinen, M., Deguchi, T., Kremneva, E., Lappalainen, P., Humphries, M. J., & Pouwels, J. (2017) · Journal of Cell Science · doi:10.1242/jcs.200329 · Cited by 14
“…a multifunctional adaptor protein that is amplified (BioPortal.org; Jung et al., 2010) and overexpressed (Bii et al., 2015; De Melo and Tang, 2015; He et al., 2010) in many human cancers and promotes cancer cell proliferation, tumour formation and metastasis (Bii et al., 2015; He et al., 2010; Li…”
BackgroundInfluentialSHARPIN S146 phosphorylation mediates ARP2/3 interaction, cancer cell invasion and metastasis
Butt, U., Khan, M. H., Pouwels, J., & Westermarck, J. (2022) · Journal of Cell Science · doi:10.1242/jcs.260627 · Cited by 6
SHARPIN serine 146 phosphorylation mediates ARP2/3 interaction, cancer cell invasion and metastasis
Butt, U., Khan, M. H., Pouwels, J., & Westermarck, J. (2022) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2022.01.21.477220 · Cited by 6
“S1A) (Bii et al., 2015, De Melo & Tang, 2015, He et al., 2010, Jung et al., 2010).”
BackgroundInfluential
Metadata
- Authors
- He, L., Ingram, A., Rybak, A. P., & Tang, D.
- Venue
- Journal of Clinical Investigation
- Published
- 2010-06-01
- Volume
- 120
- Issue
- 6
- Pages
- 2094-2108
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W2133742666
- Cited by
- 100
- References
- 6
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.